PL375113A1 - Casein derived peptides and uses thereof in therapy - Google Patents
Casein derived peptides and uses thereof in therapyInfo
- Publication number
- PL375113A1 PL375113A1 PL02375113A PL37511302A PL375113A1 PL 375113 A1 PL375113 A1 PL 375113A1 PL 02375113 A PL02375113 A PL 02375113A PL 37511302 A PL37511302 A PL 37511302A PL 375113 A1 PL375113 A1 PL 375113A1
- Authority
- PL
- Poland
- Prior art keywords
- peptides
- therapy
- casein
- derived peptides
- derived
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 239000005018 casein Substances 0.000 title abstract 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 title abstract 3
- 235000021240 caseins Nutrition 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 230000011132 hemopoiesis Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 235000013336 milk Nutrition 0.000 abstract 1
- 239000008267 milk Substances 0.000 abstract 1
- 210000004080 milk Anatomy 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/942,121 US20020147144A1 (en) | 2000-03-01 | 2001-08-30 | Casein derived peptides and uses thereof in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL375113A1 true PL375113A1 (en) | 2005-11-28 |
Family
ID=25477603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02375113A PL375113A1 (en) | 2001-08-30 | 2002-08-29 | Casein derived peptides and uses thereof in therapy |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1556074A4 (enExample) |
| JP (1) | JP2005511499A (enExample) |
| KR (1) | KR20040078639A (enExample) |
| CN (1) | CN1694719A (enExample) |
| AU (1) | AU2002324323A2 (enExample) |
| BR (1) | BR0212625A (enExample) |
| CA (1) | CA2458924A1 (enExample) |
| CZ (1) | CZ2004335A3 (enExample) |
| HU (1) | HUP0500995A3 (enExample) |
| IL (1) | IL160548A0 (enExample) |
| MX (1) | MXPA04001890A (enExample) |
| NO (1) | NO20040880L (enExample) |
| PL (1) | PL375113A1 (enExample) |
| WO (1) | WO2003018606A2 (enExample) |
| ZA (1) | ZA200401574B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0313892D0 (en) * | 2003-06-16 | 2003-07-23 | Hannah Res Inst | Control of lactation |
| AU2005209845A1 (en) * | 2004-01-30 | 2005-08-18 | Chemgenex Pharmaceuticals, Inc. | Naphthalimide dosing by N-acetyl transferase genotyping |
| BRPI0507822A (pt) * | 2004-03-01 | 2007-07-10 | Peptera Pharmaceuticals Ltd | método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição autoimune ou infecciosa, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição do sangue, método e composição farmacêutica para modular a formação de células do sangue, método e composição farmacêutica para intensificar a mobilização periférico da célula tronco, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição metabólica, método e composição farmacêutica para a prevenção ou o tratamento das condições associadas com doses mieloablativas de quimioradioterapia suportadas pelo transplante autólogo de medula óssea ou de células tronco do sangue periférico (asct) ou pelo transplante alogenéico de medula óssea (bmt), método e composição farmacêutica para aumentar o efeito de um fator estimulante de células do sangue, método e composição farmacêutica para intensificar a colonização de células tronco do sangue doadas em um receptor mieloablatado, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição bacteriana, composição farmacêutica para o tratamento ou a prevenção de uma indicação selecionada do grupo que consiste em doença ou condição autoimune, doença viral, infecção viral, doença hematológica, deficiências hematológicas, trombocitopenia, pancitopenia, granulopenia, hiperlipidemia, hipercolesterolemia, glucosuria, hiperglicemia, diabetes, aids, hiv-1, distúrbios de células t auxiliares, deficiências de células dendrìticas, deficiências de macrofagos, distúrbios de células tronco hematopoiéticas incluindo distúrbios com plaquetas, linfócitos, células do plasma e neutrófilos, condições pré-leucêmicas, condições leucêmicas, distúrbios do sistema imunológico resultantes da terapia de quimioterapia ou de radiação, distúrbios do sistema imunológico humano resultantes do tratamento das doenças de deficiência imunológica e infecções bacterianas, composição farmacêutica para o tratamento ou a prevenção de um indicação selecionada do grupo que consiste em doença hematológica, deficiências hematológicas, trombocitopenia, pancitopenia, granulopenia, deficiências de células dendrìticas, deficiências de macrofagos, distúrbios de células tronco hematopoiéticas incluindo distúrbios com plaquetas, linfócitos, células do plasma e neutrófilos, condições pré-leucêmicas, condições leucêmicas, sìndrome mielodisplástiacas, malignidades não mielóides, anemia plástica e insuficiência da medula óssea, peptìdeo purificado, peptìdeo quimérico purificado, peptìdeo quimérico, composição farmacêutica, composição farmacêutica para a prevenção ou o tratamento de uma condição associada com um agente infeccioso de sars, método de processamento a baixa temperatura de hidrolisato proteolìtico de caseìna e hidrolisato de proteìna de caseìna |
| GB0423352D0 (en) | 2004-10-21 | 2004-11-24 | Hannah Res Inst | "Control of mammary cell number" |
| ES2319475B1 (es) * | 2005-06-08 | 2010-02-16 | Consejo Superior Investig. Cientificas | Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion. |
| WO2007142230A1 (ja) | 2006-06-09 | 2007-12-13 | Morinaga Milk Industry Co., Ltd. | 脂質代謝改善剤 |
| JP2011026213A (ja) * | 2009-07-22 | 2011-02-10 | Snow Brand Milk Prod Co Ltd | １型糖尿病抑制ペプチド |
| RU2645085C2 (ru) * | 2012-04-16 | 2018-02-15 | Дзе Кливленд Клиник Фаундейшн | Мультивалентная вакцина против рака молочной железы |
| EP3590519A4 (en) * | 2017-03-03 | 2020-12-16 | Morinaga Milk Industry Co., Ltd. | GLP-1 SECRETAGOGUE AND COMPOSITION |
| CN107814835B (zh) * | 2017-12-01 | 2020-04-28 | 熊猫乳品集团股份有限公司 | 一种生物活性多肽avpitptlnreq及其制备方法和应用 |
| CN108017709B (zh) * | 2017-12-12 | 2020-04-10 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽kepmigvnqela及其制备方法和应用 |
| CN113952446B (zh) * | 2021-09-03 | 2023-12-05 | 河南省医药科学研究院 | 生物活性肽在抑制骨髓毒性中的应用 |
| CN120815163B (zh) * | 2025-09-16 | 2025-12-12 | 华中科技大学同济医学院附属同济医院 | 能抑制ccnb2表达的抗肿瘤药物和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3778426A (en) * | 1970-12-16 | 1973-12-11 | Research Corp | Therapeutically useful polypeptides |
| NZ332993A (en) * | 1997-03-21 | 2000-01-28 | Snow Brand Milk Products Co Ltd | Iron-casein complex hydrolyzate and process for the production thereof |
| IL134830A0 (en) * | 2000-03-01 | 2001-05-20 | Chay 13 Medical Res Group N V | Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them |
-
2002
- 2002-08-29 JP JP2003523265A patent/JP2005511499A/ja active Pending
- 2002-08-29 HU HU0500995A patent/HUP0500995A3/hu unknown
- 2002-08-29 CN CNA028216741A patent/CN1694719A/zh active Pending
- 2002-08-29 WO PCT/IL2002/000720 patent/WO2003018606A2/en not_active Ceased
- 2002-08-29 PL PL02375113A patent/PL375113A1/xx not_active Application Discontinuation
- 2002-08-29 AU AU2002324323A patent/AU2002324323A2/en not_active Abandoned
- 2002-08-29 CA CA002458924A patent/CA2458924A1/en not_active Abandoned
- 2002-08-29 KR KR10-2004-7002884A patent/KR20040078639A/ko not_active Withdrawn
- 2002-08-29 BR BRPI0212625-7A patent/BR0212625A/pt not_active IP Right Cessation
- 2002-08-29 IL IL16054802A patent/IL160548A0/xx unknown
- 2002-08-29 EP EP02758768A patent/EP1556074A4/en not_active Withdrawn
- 2002-08-29 MX MXPA04001890A patent/MXPA04001890A/es not_active Application Discontinuation
- 2002-08-29 CZ CZ2004335A patent/CZ2004335A3/cs unknown
-
2004
- 2004-02-26 ZA ZA200401574A patent/ZA200401574B/en unknown
- 2004-02-27 NO NO20040880A patent/NO20040880L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04001890A (es) | 2004-06-18 |
| ZA200401574B (en) | 2007-02-28 |
| CA2458924A1 (en) | 2003-03-06 |
| NO20040880L (no) | 2004-04-20 |
| HUP0500995A2 (en) | 2007-05-02 |
| EP1556074A4 (en) | 2008-05-07 |
| WO2003018606A3 (en) | 2005-05-06 |
| HUP0500995A3 (en) | 2008-09-29 |
| WO2003018606A2 (en) | 2003-03-06 |
| BR0212625A (pt) | 2007-06-19 |
| WO2003018606A9 (en) | 2004-04-08 |
| IL160548A0 (en) | 2004-07-25 |
| CN1694719A (zh) | 2005-11-09 |
| JP2005511499A (ja) | 2005-04-28 |
| AU2002324323A2 (en) | 2003-03-10 |
| EP1556074A2 (en) | 2005-07-27 |
| CZ2004335A3 (cs) | 2004-07-14 |
| KR20040078639A (ko) | 2004-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL361307A1 (en) | Casein derived peptides and uses thereof in therapy | |
| WO2005081628A3 (en) | Casein derived peptides and therapeutic uses thereof | |
| ATE314095T1 (de) | Virusähnliche partikel zur induktion von autoantikörpern | |
| PL375113A1 (en) | Casein derived peptides and uses thereof in therapy | |
| AU3698697A (en) | Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament | |
| WO2000054813A3 (en) | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye | |
| AU1685499A (en) | Polypeptide, their production and use | |
| WO2003047524A3 (en) | Methods and compositions for modulating the immune system and uses thereof | |
| GB2367061A (en) | Peptides | |
| WO2003048205A3 (fr) | Proteines a activite inhibitrice de l'il-6 | |
| FR2870126A1 (fr) | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin | |
| WO2001045738A3 (en) | Use of heat shock proteins to enhance production of chemokines by a cell | |
| WO2001004318A3 (en) | Myxoma virus genes for immune modulation | |
| GB2374871A (en) | Peptide fragments of colostrinin and their use | |
| AU5489500A (en) | Isolation of a human retrovirus | |
| WO2004006843A3 (en) | Combination therapies with l-fmau for the treatment of hepatitis b virus infection | |
| MD2053B1 (en) | Remedy with interferon inducing action | |
| GB0415437D0 (en) | Recombinant virus | |
| MXPA05007901A (es) | Terapia de combinacion para hcv. | |
| WO2001087333A3 (de) | Mittel zur stimulation des immunsystems | |
| NO964894D0 (no) | Rekombinante viruser, deres fremstilling samt anvendelse av genterapi | |
| ATE315082T1 (de) | Myeloider koloniestimulierungsfaktor und verwendungen davon | |
| WO2000024876A3 (en) | Spumavirus isolated from humans |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |